JUR-003 for metastatic prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests an experimental drug called JUR-003 in people with prostate cancer that has spread to other parts of the body. It aims to see if the drug can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of prostate cancer that has spread (metastatic).
- You must have tumors that can be measured on scans or other signs of cancer that can be tracked.
- You must not have a weakened immune system or have had an organ or stem cell transplant.
- You must not have active hepatitis B or C, HIV, or an autoimmune disease that needed treatment in the last 2 years.
- You must not have untreated spinal cord compression or unstable brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new immunotherapy drug called JANX014 in men with advanced prostate cancer that has stopped responding to hormone treatments. The trial aims to find the right dose and see if this drug can help slow or stop cancer growth.
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
This study tests a new drug called mevrometostat for men with a specific type of advanced prostate cancer that has spread and is still growing despite hormone therapy. It aims to see if the drug can help control the cancer.
This Phase 1 trial tests JANX007 in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite standard hormone treatment). It aims to find a safe dose and see whether the treatment can shrink tumors or slow progression.
This trial tests a new targeted therapy (DEC003M) for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to see if this treatment is safe and helps shrink tumors.
This trial tests an experimental drug (JNJ-101556143) for men with metastatic prostate cancer that has stopped responding to hormone therapy. The goal is to see if this drug can slow down or stop the cancer from growing.
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.